Akero Therapeutics Sponsored Study Titled 'A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)' Posted To ClinicalTrials.Gov; Study Is Recruiting